ATHE - Alterity Therapeutics Price to Sales
The completion of Phase II trials for its Parkinson's disease drug will be the key driver for Alterity Therapeutics (ATHE), with the current metric value standing at 2.20. P/S fluctuations visualize market expectations amid a lack of profitability. Alterity Therapeutics (ATHE) is implementing bioethical principles and minimizing chemical waste. Patient safety is guaranteed by strict temperature control during the transportation of medications to clinics.
Analytical breakdowns for Alterity Therapeutics (ATHE)
- stock quotes and analyst forecast:
- market capitalization statistics:
- shareholders' equity book value data:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Alterity Therapeutics|ATHE - Long-Term Debt to Capital|Current Liabilities to Capital Alterity Therapeutics Ltd.|ATHE - Company Debts|Debt to Net Assets Ratio Alterity Therapeutics Limited|ATHE - Company Long-Term Debts|Company Short-Term Debts Alterity Therapeutics|Critical Liquidity Ratio alteritytherapeutics.com
- earnings and valuation multiples information:
ATHE - Net Profit|Expected Net Profit Alterity Therapeutics|ATHE - Price to Earnings Ratio|Forward P/E Multiple Alterity Therapeutics Ltd|ATHE - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Alterity Therapeutics Limited|ATHE - Operating profit EBITDA|Net earnings per share for the last four quarters Alterity Therapeutics|ATHE - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months alteritytherapeutics.com|ATHE - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Alterity Therapeutics
- sales revenue and business income indicators:
Fundamental company analysis:Alterity Therapeutics Ltd, ATHE
To diversify my portfolio with high-quality assets, I utilize the valuation of market capitalization relative to annual revenue. This metric measures the cost of one dollar of sales, determining the extent of the premium paid for the business. For Alterity Therapeutics (ATHE), with its exclusive patents for brain degeneration drugs, this calculation reflects market expectations for future R&D success. The current price-to-sales ratio of 2.20 allows for a timely adjustment of the investment strategy.
Competing companies
BIIB (Biogen) - Market Capitalization-to-Revenue Ratio|P/S Multiple NBIX (Neurocrine Corp)|Regencell Bioscience - Price-to-Revenue Ratio|Axsome Therapeutics - P/S Multiple|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Price-to-Revenue Ratio|Price to Sales Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - P/S Multiple|CPRX: Market Capitalization-to-Revenue Ratio|P/S Multiple DNLI|Price-to-Revenue Coefficient Harmony Biosciences|Biohaven Ltd - Market Cap to Revenue|P/S Multiple Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Market Cap to Revenue|Price-to-Revenue Coefficient Praxis Corp PRAX|AVXL: P/S Multiple|CBLL (ceribell.com) - Price-to-Revenue Ratio|PRTA (Prothena Corporation) - P/S Multiple|Market Cap to Revenue alector.com (ALEC)|Price-to-Revenue Ratio Annexon, Inc. (ANNX)|OMER - Price to Sales|P/S Multiple NGNE (Neurogene Inc)|AC Immune (ACIU) - Price to Sales|Voyager Therapeutics Inc - P/S Multiple|Neumora (NMRA) - Market Cap to Revenue|SCLX: P/S Multiple|TVGN - Price-to-Revenue Coefficient|ACOG (Alpha Cognition Inc) - P/S Multiple|Market Cap to Revenue cogrx.com (CGTX)|Price-to-Revenue Ratio Inhibikase Therapeutics Inc (IKT)|Price-to-Revenue Coefficient Cassava Sciences|P/S Multiple ASRT (Assertio Holdings)|COYA - Market Cap to Revenue|vistagen.com - P/S Multiple|OVID: Price-to-Revenue Ratio|Acumen Pharmaceuticals, Inc (ABOS) - Price-to-Revenue Ratio|CervoMed Inc - Market Capitalization-to-Revenue Ratio|CLNN (Clene) - P/S Multiple|Market Cap to Revenue Ratio PEPG (PepGen)|Market Cap to Revenue JUNS (Jupiter Neurosciences, Inc.)|P/S Multiple relmada.com (RLMD)|Price-to-Revenue Ratio Annovis Bio Corp ANVS|GRCE: Market Cap to Revenue Ratio|AIFF - Price-to-Revenue Ratio|KLTO (anewmeds.com) - Market Cap to Revenue Ratio|NRSN (NeuroSense Therapeutics Ltd.) - Market Cap to Revenue|revivapharma.com - Market Capitalization-to-Revenue Ratio|MTVA (metaviatx.com) - P/S Multiple|NRXS: Market Capitalization-to-Revenue Ratio|P/S Multiple HSDT|PASG - Price to Sales|P/S Multiple NEUP (Neuphoria Therapeutics)|NERV: Market Cap to Revenue Ratio|ATHA: Market Cap to Revenue|Addex Therapeutics Ltd - Market Cap to Sales Volume|Alzamend Neuro, Inc. (ALZN) - Price-to-Revenue Ratio|CYCN (Cyclerion Therapeutics Inc.) - Price-to-Revenue Ratio|Market Cap to Revenue PTIX|KTTA: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue CRGT (Cortigent Medical)|ATXI (Avenue Therapeutics, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Brainstorm Cell Therapeutics, Inc. BCLI|Market Capitalization-to-Revenue Ratio CARA|chromocell.com - P/S Multiple|Price-to-Sales Ratio ELYM|ITCI: P/S Multiple|Price to Sales Longboard Pharmaceuticals, Inc. (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGN: Market Capitalization-to-Revenue Ratio|P/S Multiple NRBO|SAGE: Price-to-Sales Ratio|Synaptogenix Inc. - Market Cap to Revenue|Market Cap to Sales Volume TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - P/S Multiple|Anew Medical (WENA) - Market Cap to Revenue|CERE (Cerevel Corp) - Market Cap to Revenue
